CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

pembrolizumab

Last Updated: March 11, 2021
Result type: Reports
Project Number: PC0236-000
Product Line: Reimbursement Review

Generic Name: pembrolizumab

Brand Name: Keytruda

Manufacturer: Merck Canada

Therapeutic Area: Classical Hodgkin lymphoma

Indications: Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT.

Manufacturer Requested Reimbursement Criteria1: Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT.

Submission Type: Initial

Tumour Type: Lymphoma

NOC Status at Filing: Pre NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule1: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openDecember 10, 2020
Call for patient/clinician input closedFebruary 05, 2021
Clarification:

- Patient input submission received from Lymphoma Canada

Submission receivedJanuary 29, 2021
Submission accepted-
Review initiatedMarch 11, 2021
Draft CADTH review report(s) provided to sponsor for commentMay 26, 2021
Deadline for sponsors commentsJune 04, 2021
CADTH responses on draft review report(s) provided to sponsorJuly 05, 2021
Expert committee meeting (initial)July 15, 2021
Draft recommendation issued to sponsorJuly 27, 2021
To
July 29, 2021
Draft recommendation posted for stakeholder feedback-